SCYNEXIS has identified unique compound collections that have not been exploited as potential starting points for the development of new treatments for parasitic diseases through partnerships with Biotech and small/medium-sized Pharma companies. These compound sets are being evaluated in the SCYNEXIS Integrated Parasitology platform to allow for the rapid assessment of these collections against multiple parasitic species. Once series of interest have been identified as high-value for Animal, Human and or Public Health, SCYNEXIS brings together your company and the company with the compound collection. Through this alliance, you rapidly realize the value of the compound series as aligned with your Target Product Profile (TPP).

We would be happy to discuss our technical expertise and business model with you in more detail to determine opportunities to work with your organization.